Physician profile
Jeffrey Mariano Sicat
NPI 1407883689
$656,624.60
in general payments reported to CMS, 2019-2025
12 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $64K · 2021: $77K · 2022: $90K · 2023: $49K · 2024: $161K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $296K · Travel and Lodging: $30K · Food and Beverage: $8,707 · Consulting Fee: $7,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $295,712.64 |
| Travel and Lodging | $29,593.31 |
| Food and Beverage | $8,706.54 |
| Consulting Fee | $7,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460,837.16 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $182,667.55 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,643.53 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $136.65 | 2019-2024 | Contrave, Nexlizet, Nexletol |
| Abbott Laboratories | $104.91 | 2021-2024 | Freestyle Libre 3 |
| Vivus LLC | $86.00 | 2022 | |
| Eisai INC. | $45.84 | 2019 | |
| Dexcom, INC. | $37.12 | 2025 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $19.93 | 2019 | |
| Amgen INC. | $17.95 | 2025 | |
| Endo Pharmaceuticals INC. | $15.01 | 2021 | |
| Kvk-Tech, INC. | $12.95 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sicat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.